Drugs / GWN323
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02740270 | Jul 2016 → Mar 2020 | cancer, lymphoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GWN323 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02740270 ↗ |
| Action | Inhibit | “GWN323 (anti-GITR)” NCT02740270 ↗ |
| Modality | Monoclonal antibody | “GWN323 is an IgG1 monoclonal antibody (mAb)” PMID 34389618 ↗ Aug 2021 |
| Route | Intravenous | “were administered intravenously at various dose levels and schedules” PMID 34389618 ↗ Aug 2021 |